Peritoneal Malignant Mesothelioma

subtype

Identifier: CI-CAN-00001410
Entity page: /cancer/peritoneal-malignant-mesothelioma ↗
Edges: 21

Neighbours: 10 drugs10 trials
Drawn: 20 of 20 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Peritoneal Malignant Mesothelioma investigated in trials for …INVESTIGATED_IN_TRIALSderived10 of 10
→ investigated in trials for	Pemetrexedsmall molecule 3 trials (3 active) · roll-up of the cancer and its descendants	—	—	Peritoneal Malignant Mesothelioma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Atezolizumabmonoclonal antibody 2 trials (2 active) · roll-up of the cancer and its descendants

Peritoneal Malignant Mesothelioma studied in …STUDIED_INderived10 of 11show all (up to 200)
→ studied in	NCT06057935Phase 2 · recruiting A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma · condition mapped ALIAS · 11 trials mapped (6 active)	—	—	Peritoneal Malignant Mesothelioma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05001880Phase 2 · recruiting Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma · condition mapped ONTOLOGY_EXACT · 11 trials mapped (6 active)	—	—	Peritoneal Malignant Mesothelioma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03074513Phase 2 · active not recruiting Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors · condition mapped CURATED_BROADER · 11 trials mapped (6 active)	—	—	Peritoneal Malignant Mesothelioma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02535312Phase 1/Phase 2 · active not recruiting Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin · condition mapped CURATED_BROADER · 11 trials mapped (6 active)	—	—	Peritoneal Malignant Mesothelioma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06756035Phase 1 · recruiting CT-95 in Advanced Cancers Associated With Mesothelin Expression · condition mapped CURATED_BROADER · 11 trials mapped (6 active)	—	—	Peritoneal Malignant Mesothelioma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02399371Phase 2 · completed Pembrolizumab in Treating Patients With Malignant Mesothelioma · condition mapped ONTOLOGY_EXACT · 11 trials mapped (6 active)	—	—	Peritoneal Malignant Mesothelioma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05449366Phase 1/Phase 2 · completed Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma · condition mapped ONTOLOGY_EXACT · 11 trials mapped (6 active)	—	—	Peritoneal Malignant Mesothelioma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06543069Phase 2 · recruiting Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM · condition mapped CURATED_BROADER · 11 trials mapped (6 active)	—	—	Peritoneal Malignant Mesothelioma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05193006unknown Assessment of Histologic Prognostic Factors in Peritoneal Malignant Mesothelioma · condition mapped ONTOLOGY_EXACT · 11 trials mapped (6 active)	—	—	Peritoneal Malignant Mesothelioma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02151448Phase 1/Phase 2 · completed αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies · condition mapped ALIAS · 11 trials mapped (6 active)	—	—	Peritoneal Malignant Mesothelioma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains